RedHill Biopharma (RDHL) Receivables - Net (2016 - 2025)

RedHill Biopharma (RDHL) has 10 years of Receivables - Net data on file, last reported at $79000.0 in Q4 2025.

• On a quarterly basis, Receivables - Net fell 96.89% year-over-year to $79000.0 in Q4 2025; TTM through Dec 2025 was $79000.0, a 96.89% decrease from a year earlier, with the FY2025 full-year figure at $79000.0, down 96.89% from the prior year.
• Receivables - Net for Q4 2025 stood at $79000.0, down from $2.5 million in the prior quarter.
• Over the last five years, Receivables - Net for RDHL reached as high as $34.5 million in Q4 2022 and fell as low as $79000.0 in Q4 2025.
• Historically, Receivables - Net has averaged $14.3 million across 5 years, with a median of $2.6 million in 2023.
• Across the five-year window, Receivables - Net advanced 10.55% in 2021 and sank 96.89% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then slumped by 92.49% to $2.6 million in 2023, then slipped by 2.01% to $2.5 million in 2024, then sank by 96.89% to $79000.0 in 2025.
• Per Business Quant data, the three most recent Receivables - Net figures were $79000.0 in Q4 2025, $2.5 million in Q4 2024, and $2.6 million in Q4 2023.